NO20065456L - Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet - Google Patents
Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemetInfo
- Publication number
- NO20065456L NO20065456L NO20065456A NO20065456A NO20065456L NO 20065456 L NO20065456 L NO 20065456L NO 20065456 A NO20065456 A NO 20065456A NO 20065456 A NO20065456 A NO 20065456A NO 20065456 L NO20065456 L NO 20065456L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- nervous system
- central nervous
- system disorders
- substituted morpholine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Foreliggende oppfinnelse angår forbindelser med formel (I), (II), (III) hvori R1 -R8 A, X og Z er som definert i beskrivelsen, farmasøytiske sammensetninger som inneholder dem og deres anvendelse ved behandling av sentralnervesystemforstyrrelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56724404P | 2004-04-30 | 2004-04-30 | |
PCT/IB2005/001158 WO2005105763A1 (en) | 2004-04-30 | 2005-04-19 | Substituted morpholine compounds for the treatment of central nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065456L true NO20065456L (no) | 2007-01-04 |
Family
ID=34965714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065456A NO20065456L (no) | 2004-04-30 | 2006-11-27 | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet |
Country Status (28)
Country | Link |
---|---|
US (1) | US7659394B2 (no) |
EP (1) | EP1745029A1 (no) |
JP (2) | JP4185154B2 (no) |
KR (1) | KR100943555B1 (no) |
CN (1) | CN1950348A (no) |
AP (1) | AP2006003771A0 (no) |
AR (1) | AR049335A1 (no) |
AU (1) | AU2005238296A1 (no) |
BR (1) | BRPI0510453A (no) |
CA (1) | CA2564994A1 (no) |
CR (1) | CR8718A (no) |
EA (1) | EA200601798A1 (no) |
EC (1) | ECSP066962A (no) |
GE (1) | GEP20084550B (no) |
GT (1) | GT200500097A (no) |
IL (1) | IL178648A0 (no) |
MA (1) | MA28555B1 (no) |
MX (1) | MXPA06012505A (no) |
NL (1) | NL1028924C2 (no) |
NO (1) | NO20065456L (no) |
PA (1) | PA8631301A1 (no) |
PE (1) | PE20060680A1 (no) |
SV (1) | SV2006002098A (no) |
TN (1) | TNSN06348A1 (no) |
TW (1) | TW200600506A (no) |
UY (1) | UY28876A1 (no) |
WO (1) | WO2005105763A1 (no) |
ZA (1) | ZA200608628B (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ332762A (en) | 1996-07-24 | 2000-09-29 | Warner Lambert Co | Isobutylgaba and its derivatives for the treatment of pain |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
CA2564994A1 (en) * | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
CA2641304A1 (en) * | 2006-02-01 | 2007-08-09 | Merck & Co., Inc. | Potassium channel inhibitors |
EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
US7531519B2 (en) * | 2006-09-21 | 2009-05-12 | Medical And Pharmaceutical Industry Technology And Development Center | Polygalatenosides and use thereof as an antidepressant agent |
TW200846002A (en) * | 2007-03-15 | 2008-12-01 | Astellas Pharma Inc | Novel prophylactic and/or therapeutic agent for diabetic neuropathy |
TW200846003A (en) * | 2007-03-15 | 2008-12-01 | Astellas Pharma Inc | Novel prophylactic and/or therapeutic agent for diabetic neuropathy |
ES2553891T3 (es) * | 2007-06-04 | 2015-12-14 | Intra-Cellular Therapies, Inc. | Derivados de piridina como moduladores NET/SERT |
US7888386B2 (en) * | 2008-07-24 | 2011-02-15 | Theravance, Inc. | 3-(phenoxyphenylmethyl)pyrrolidine compounds |
CA2742114C (en) | 2008-11-14 | 2016-09-13 | Theravance, Inc. | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound |
GEP20135992B (en) | 2009-01-12 | 2013-12-25 | Icagen Inc | Sulfonamide derivatives |
US8474529B2 (en) * | 2009-04-09 | 2013-07-02 | Regency Technologies Llc | Control of concentric tubing direction |
AR075988A1 (es) | 2009-04-09 | 2011-05-11 | Lilly Co Eli | Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico |
EP2419405A1 (en) * | 2009-04-15 | 2012-02-22 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
ES2675791T3 (es) * | 2009-07-13 | 2018-07-12 | Theravance Biopharma R&D Ip, Llc | Compuesto 3-fenoximetilpirrolidina |
WO2011011231A1 (en) | 2009-07-21 | 2011-01-27 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
UY32858A (es) * | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
EP2523945A1 (en) * | 2010-01-11 | 2012-11-21 | Theravance, Inc. | 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors |
EP2550252B1 (en) * | 2010-03-22 | 2015-05-06 | Theravance Biopharma R&D IP, LLC | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
RU2012155839A (ru) | 2010-05-24 | 2014-06-27 | Фаэс Фарма, С.А. | Производные флуфеноксина для лечения и предупреждения амилоидных патологий |
EP2390248A1 (en) | 2010-05-24 | 2011-11-30 | Faes Farma, S.A. | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies |
TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
TW201206893A (en) * | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
JP5873877B2 (ja) | 2010-10-11 | 2016-03-01 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | セロトニン再取込みインヒビター |
US8501964B2 (en) | 2010-12-03 | 2013-08-06 | Theravance, Inc. | Serotonin reuptake inhibitors |
JP2012207995A (ja) * | 2011-03-29 | 2012-10-25 | Univ Of Fukui | 脳内ノルエピネフリン・トランスポータを標的とする放射性臭素標識pet分子イメージングプローブ |
EP2745876A1 (en) | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
SG10201913878YA (en) | 2016-03-17 | 2020-03-30 | Hoffmann La Roche | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
AU2020373047A1 (en) | 2019-10-31 | 2022-05-19 | ESCAPE Bio, Inc. | Solid forms of an S1P-receptor modulator |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1138405A (en) * | 1966-12-28 | 1969-01-01 | Ici Ltd | Morpholine derivatives |
GB1260886A (en) * | 1969-06-20 | 1972-01-19 | Ici Ltd | Process for aryloxymethylmorpholine derivatives |
BE759013R (fr) | 1969-11-17 | 1971-05-17 | Ici Ltd | Derives de la |
BE758766A (fr) * | 1969-11-17 | 1971-05-10 | Ici Ltd | Nouveaux derives de la morpholine et de la |
US4116665A (en) | 1976-04-02 | 1978-09-26 | Eli Lilly And Company | Method of regulating the growth of aquatic weeds with pyridine derivatives |
DE2715138B2 (de) | 1977-04-05 | 1980-02-07 | Forbach Gmbh & Co Kg, 8740 Bad Neustadt | Wasserbehälter aus Kunststoff fur einen Heißwasserbereiter |
IT1093255B (it) | 1978-01-20 | 1985-07-19 | Erba Carlo Spa | Derivati fenossialcanolaminici |
IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
CA1215067A (en) | 1982-10-18 | 1986-12-09 | Sudarshan K. Malhotra | 2-(6-phenoxy-3-nitro-2-pyridinoxy)-propionate compounds |
GB8419683D0 (en) | 1984-08-02 | 1984-09-05 | Erba Farmitalia | 3-substituted derivatives of 1-amino-2-hydroxy-propane |
GB2167407B (en) | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
US4855143A (en) * | 1986-04-04 | 1989-08-08 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
US5750532A (en) | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
US5272167A (en) | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
FR2612926B1 (fr) | 1987-03-24 | 1989-06-09 | Adir | Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
FR2653999A1 (fr) | 1989-11-06 | 1991-05-10 | Adir | Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
JPH04185154A (ja) * | 1990-11-20 | 1992-07-02 | Nec Corp | 中継台接続制御方式 |
AU642582B2 (en) | 1991-02-25 | 1993-10-21 | Eli Lilly And Company | Treatment of lower urinary tract disorders |
US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
US5559135A (en) | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
TW375612B (en) | 1995-04-06 | 1999-12-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same |
JP3969741B2 (ja) | 1995-11-17 | 2007-09-05 | マーク アンド カンパニー インコーポレイテッド | アセチルコリン受容体の修飾因子として役立つ新規置換アリール化合物 |
UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
US6423708B1 (en) | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US5945117A (en) | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
KR20060120715A (ko) | 1998-03-31 | 2006-11-27 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 수용체에 대해 활성을 갖는 화합물 |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
NZ507022A (en) | 1998-04-01 | 2002-06-28 | Janssen Pharmaceutica Nv | PDE IV inhibiting pyridine derivatives |
WO2000009491A1 (en) * | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
AU764492B2 (en) | 1998-12-29 | 2003-08-21 | Pharmacia & Upjohn Company | Method for the preparation of aryl ethers |
ATE313319T1 (de) | 1999-03-31 | 2006-01-15 | Janssen Pharmaceutica Nv | Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe |
EA011094B1 (ru) | 1999-07-01 | 2008-12-30 | Фармация Энд Апджон Компани | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
CA2383466C (en) | 1999-09-16 | 2009-08-25 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogen-containing 6-membered cyclic compounds |
IL150059A0 (en) | 1999-12-17 | 2002-12-01 | Ariad Pharma Inc | Novel heterocycles |
EA200300834A1 (ru) | 2000-01-18 | 2004-02-26 | Пфайзер Продактс Инк. | Антагонисты фактора, высвобождающего кортикотропин |
AU2001241142B2 (en) | 2000-04-28 | 2005-09-22 | Tanabe Seiyaku Co., Ltd. | Cyclic compounds |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
WO2002036125A1 (en) | 2000-10-31 | 2002-05-10 | Head Explorer A/S | The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
WO2002053104A2 (en) | 2001-01-02 | 2002-07-11 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
JP2005511560A (ja) | 2001-11-01 | 2005-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | コレステロール生合成経路の変調 |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US20040034101A1 (en) | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
AU2002352625A1 (en) * | 2001-12-11 | 2003-06-23 | Eli Lilly And Company | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
EP1911740B1 (en) | 2002-01-04 | 2013-02-27 | NeuroSearch A/S | Potassium channel modulators |
US20050009927A1 (en) | 2002-01-23 | 2005-01-13 | Pfizer Inc | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
US6962932B2 (en) | 2002-02-15 | 2005-11-08 | Schering Aktiengesellschaft | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
EP1485078B1 (en) | 2002-03-15 | 2012-09-26 | Cypress Bioscience, Inc. | Milnacipran for the treatment of irritable bowel syndrome |
GB0215392D0 (en) | 2002-07-03 | 2002-08-14 | Glaxo Group Ltd | Chemical compounds |
US20040034019A1 (en) | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
GB2409719B (en) | 2002-08-15 | 2006-03-29 | Schlumberger Holdings | Use of distributed temperature sensors during wellbore treatments |
WO2004017977A2 (en) * | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
EP1546123B1 (en) * | 2002-08-23 | 2006-05-31 | Eli Lilly And Company | Benzyl morpholine derivatives |
WO2004048860A1 (fr) | 2002-11-27 | 2004-06-10 | Chabanov Alim I | Procede pour construire des installations energetiques solaires haute puissance |
JP2004189738A (ja) | 2002-11-29 | 2004-07-08 | Nippon Nohyaku Co Ltd | 置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法 |
WO2004058353A2 (en) | 2002-12-24 | 2004-07-15 | Paradigm Therapeutics Ltd. | Therapeutic use of selective noradrenaline reuptake inhibitors |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
GB0319793D0 (en) * | 2003-08-22 | 2003-09-24 | Lilly Co Eli | Pyridinylmorpholine derivatives |
WO2005020976A2 (en) | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
CA2530014A1 (en) | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
EP1660185A2 (en) | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors |
KR20060087560A (ko) | 2003-09-12 | 2006-08-02 | 워너-램버트 캄파니 엘엘씨 | 알파-2-델타 리간드 및 ssri 및/또는 snri를포함하는 우울증 및 불안 장애 치료용 조합물 |
WO2005066144A1 (en) | 2003-12-23 | 2005-07-21 | Eli Lilly And Company | Morpholine derivatives as norepinephrine reuptake inhibitors |
DE102004005545B4 (de) | 2004-02-04 | 2018-10-31 | Siemens Healthcare Gmbh | Verbindungsanordnung und Flachbaugruppe |
CA2564994A1 (en) * | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
GB0409744D0 (en) | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
-
2005
- 2005-04-19 CA CA002564994A patent/CA2564994A1/en not_active Abandoned
- 2005-04-19 KR KR1020067022767A patent/KR100943555B1/ko not_active IP Right Cessation
- 2005-04-19 WO PCT/IB2005/001158 patent/WO2005105763A1/en active Application Filing
- 2005-04-19 CN CNA2005800137766A patent/CN1950348A/zh active Pending
- 2005-04-19 BR BRPI0510453-0A patent/BRPI0510453A/pt not_active IP Right Cessation
- 2005-04-19 AP AP2006003771A patent/AP2006003771A0/xx unknown
- 2005-04-19 EP EP05733459A patent/EP1745029A1/en not_active Withdrawn
- 2005-04-19 EA EA200601798A patent/EA200601798A1/ru unknown
- 2005-04-19 GE GEAP20059682A patent/GEP20084550B/en unknown
- 2005-04-19 JP JP2007510153A patent/JP4185154B2/ja not_active Expired - Fee Related
- 2005-04-19 AU AU2005238296A patent/AU2005238296A1/en not_active Abandoned
- 2005-04-19 MX MXPA06012505A patent/MXPA06012505A/es unknown
- 2005-04-27 PA PA20058631301A patent/PA8631301A1/es unknown
- 2005-04-28 GT GT200500097A patent/GT200500097A/es unknown
- 2005-04-28 PE PE2005000480A patent/PE20060680A1/es not_active Application Discontinuation
- 2005-04-28 AR ARP050101667A patent/AR049335A1/es unknown
- 2005-04-28 UY UY28876A patent/UY28876A1/es not_active Application Discontinuation
- 2005-04-29 TW TW094113971A patent/TW200600506A/zh unknown
- 2005-04-29 NL NL1028924A patent/NL1028924C2/nl not_active IP Right Cessation
- 2005-04-29 SV SV2005002098A patent/SV2006002098A/es not_active Application Discontinuation
- 2005-04-29 US US11/119,210 patent/US7659394B2/en not_active Expired - Fee Related
-
2006
- 2006-10-16 IL IL178648A patent/IL178648A0/en unknown
- 2006-10-16 ZA ZA200608628A patent/ZA200608628B/xx unknown
- 2006-10-27 CR CR8718A patent/CR8718A/es not_active Application Discontinuation
- 2006-10-27 TN TNP2006000348A patent/TNSN06348A1/fr unknown
- 2006-10-30 EC EC2006006962A patent/ECSP066962A/es unknown
- 2006-10-30 MA MA29418A patent/MA28555B1/fr unknown
- 2006-11-27 NO NO20065456A patent/NO20065456L/no not_active Application Discontinuation
-
2007
- 2007-09-07 JP JP2007233201A patent/JP2008019267A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BRPI0510453A (pt) | 2007-10-30 |
PA8631301A1 (es) | 2006-05-16 |
ECSP066962A (es) | 2006-12-20 |
EP1745029A1 (en) | 2007-01-24 |
ZA200608628B (en) | 2009-01-28 |
KR100943555B1 (ko) | 2010-02-22 |
CN1950348A (zh) | 2007-04-18 |
PE20060680A1 (es) | 2006-08-11 |
NL1028924A1 (nl) | 2005-11-01 |
CR8718A (es) | 2007-07-24 |
NL1028924C2 (nl) | 2006-04-27 |
CA2564994A1 (en) | 2005-11-10 |
IL178648A0 (en) | 2007-02-11 |
GT200500097A (es) | 2005-12-12 |
JP2007535530A (ja) | 2007-12-06 |
TNSN06348A1 (fr) | 2008-02-22 |
KR20070006881A (ko) | 2007-01-11 |
MA28555B1 (fr) | 2007-04-03 |
AP2006003771A0 (en) | 2006-10-31 |
SV2006002098A (es) | 2006-02-15 |
US20050245519A1 (en) | 2005-11-03 |
TW200600506A (en) | 2006-01-01 |
EA200601798A1 (ru) | 2007-04-27 |
JP4185154B2 (ja) | 2008-11-26 |
AR049335A1 (es) | 2006-07-19 |
UY28876A1 (es) | 2005-11-30 |
MXPA06012505A (es) | 2006-12-15 |
US7659394B2 (en) | 2010-02-09 |
WO2005105763A1 (en) | 2005-11-10 |
GEP20084550B (en) | 2008-11-25 |
JP2008019267A (ja) | 2008-01-31 |
AU2005238296A1 (en) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
NO20060324L (no) | [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni | |
NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
NO20051826L (no) | Heterosyklisk substituerte piperaziner for behandling av schizofreni | |
NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
NO20076196L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO331068B1 (no) | Benzazepinderivater for behandling av nevrologiske forstyrrelser. | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
NO20073572L (no) | Nye forbindelser | |
NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
NO20076137L (no) | Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi | |
NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
NO20061700L (no) | 2-pyridonderivater som neutrofil elastase inhibitorer og deres anvendelse | |
NO20084712L (no) | Nye farmasoytiske forbindelser | |
NO20081217L (no) | Nye benzotiazolonderivater | |
NO20063928L (no) | Substituerte kinolinforbindelser | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20092412L (no) | Hydantoinderivater anvendes som MMP-inhibitorer | |
NO20055688L (no) | Organiske forbindelser | |
NO20084845L (no) | 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig | |
NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
NO20076138L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
NO20074258L (no) | Pyridin-2-karboksamidderivater som MGLUR5 antagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |